Trenbolone for HRT - Better than testosterone?
Has the thought crossed your mind that testosterone is not the optimal androgen? I mean we all take medications to produce an effect that we believe is better, is there an androgen that is better tailored for longevity and wellness?
Consider CANCER, prostate cancer being the most prevalent one in males and is of great concern to every male as we age. Testosterone converts to DHT which is an androgen that targets prostate specific tissue. Sure, there isn't conclusive evidence that an excess in androgens will lead to prostate cancer BUT we can assume the less prostate related AR activation we endure, the better.
So, now would I personally move on to trenbolone HRT? Hell yes I would, IF there were some modifications done to the program. The main problem I see with trenbolone is the lack of aromatase, personally with testosterone I aromatase way too much I do not like that compound. Seriously, but if you consider that hCG would be prescribed along side the HRT that should give you enough estrogen to be healthy AND reduce the need for an AI. Hematocrit levels would improve to the point so that you do not have to donate blood every two months. If you consider the guys on HRT here, we all like a lot of androgens. The supraphysiological levels of testosterone produces supraphysiological levels of estrogen as well and then we have to supply an AI to combat the effects of testosterone.
I am not saying that trenbolone is the best androgen that should be used, but I believe that we should at least have an open mind to the possibility of using other androgens to optimize our health. Other androgens + hCG may be a better option. Masteron and hCG perhaps, the competition of estrogen at the receptor may be advantageous if hCG brings your e2 too high.
Mainpoints: Try to move away from testosterone as the main problem with testosterone is the DHT conversion leading to possible PROSTATE CANCER and supraphysiological levels of e2.
What are your opinions? Is testosterone the best androgen for HRT and why? What are the CONS of testosterone use that possibly other androgens can bypass?
17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate
http://ajpendo.physiology.org/content/300/4/E650.full
Abstract
Selective androgen receptor modulators (SARMs) now under development can protect against muscle and bone loss without causing prostate growth or polycythemia. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analog, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α-reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations. Male F344 rats aged 3 mo underwent orchiectomy or remained intact and were administered graded doses of TREN, supraphysiological testosterone-enanthate, or vehicle for 29 days. In both intact and orchiectomized animals, all TREN doses and supraphysiological testosterone-enanthate augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35–40% above shams (P ≤ 0.001) and produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (P < 0.05) and visceral fat accumulation (P < 0.05). The lowest doses of TREN successfully maintained prostate mass and hemoglobin concentrations at sham levels in both intact and orchiectomized animals, whereas supraphysiological testosterone-enanthate and high-dose TREN elevated prostate mass by 84 and 68%, respectively (P < 0.01). In summary, low-dose administration of the non-5α-reducible androgen TREN maintains prostate mass and hemoglobin concentrations near the level of shams while producing potent myotrophic actions in skeletal muscle and partial protection against orchiectomy-induced bone loss and visceral fat accumulation. Our findings indicate that TREN has advantages over supraphysiological testosterone and supports the need for future preclinical studies examining the viability of TREN as an option for androgen replacement therapy.